Buy Rating Affirmed for Seres Therapeutics' SER-155 Amid Anticipated Positive Impact on Infection and GvHD Rates
Bears Are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
Seres Therapeutics Releases Financial Statements Ahead of Asset Sale
Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Seres Therapeutics (MCRB) Gets a Hold From Oppenheimer
Buy Rating on Seres Therapeutics: Strategic Growth and Promising Clinical Trials Fuel Analyst Confidence
Express News | Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
Q2 2024 Seres Therapeutics Inc Earnings Call
Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $1.25
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Strong Sales and Promising Trials Underpin Buy Rating for Seres Therapeutics
Earnings Call: Seres Therapeutics Sells VOWST Assets to Nestle for $155 Million
Earnings Call Summary | Seres Therapeutics(MCRB.US) Q2 2024 Earnings Conference
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
Seres Therapeutics | 10-Q: Q2 2024 Earnings Report
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Seres Therapeutics, Inc. Buyout
Seres Therapeutics Unveils Updated Corporate Presentation
Express News | Seres Therapeutics Q2 2024 GAAP EPS $(0.22) Beats $(0.27) Estimate, $71.2M In Cash And Cash Equivalents That Is Expected To Fund Operations Into The Fourth Quarter Of 2025